S&P 500   3,961.65 (+0.33%)
DOW   32,190.48 (+0.27%)
QQQ   310.06 (+0.10%)
AAPL   159.92 (+0.62%)
MSFT   279.01 (+0.49%)
META   205.54 (+0.62%)
GOOGL   105.05 (-0.52%)
AMZN   98.11 (-0.61%)
TSLA   190.19 (-1.06%)
NVDA   266.45 (-2.01%)
NIO   9.03 (-2.59%)
BABA   86.70 (+0.21%)
AMD   97.79 (-2.48%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   60.72 (-1.01%)
CGC   1.92 (+0.52%)
GE   90.86 (-0.80%)
DIS   94.08 (-1.83%)
AMC   4.50 (+0.67%)
PFE   40.38 (+0.50%)
PYPL   73.54 (+1.35%)
NFLX   327.63 (+2.27%)
S&P 500   3,961.65 (+0.33%)
DOW   32,190.48 (+0.27%)
QQQ   310.06 (+0.10%)
AAPL   159.92 (+0.62%)
MSFT   279.01 (+0.49%)
META   205.54 (+0.62%)
GOOGL   105.05 (-0.52%)
AMZN   98.11 (-0.61%)
TSLA   190.19 (-1.06%)
NVDA   266.45 (-2.01%)
NIO   9.03 (-2.59%)
BABA   86.70 (+0.21%)
AMD   97.79 (-2.48%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   60.72 (-1.01%)
CGC   1.92 (+0.52%)
GE   90.86 (-0.80%)
DIS   94.08 (-1.83%)
AMC   4.50 (+0.67%)
PFE   40.38 (+0.50%)
PYPL   73.54 (+1.35%)
NFLX   327.63 (+2.27%)
S&P 500   3,961.65 (+0.33%)
DOW   32,190.48 (+0.27%)
QQQ   310.06 (+0.10%)
AAPL   159.92 (+0.62%)
MSFT   279.01 (+0.49%)
META   205.54 (+0.62%)
GOOGL   105.05 (-0.52%)
AMZN   98.11 (-0.61%)
TSLA   190.19 (-1.06%)
NVDA   266.45 (-2.01%)
NIO   9.03 (-2.59%)
BABA   86.70 (+0.21%)
AMD   97.79 (-2.48%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   60.72 (-1.01%)
CGC   1.92 (+0.52%)
GE   90.86 (-0.80%)
DIS   94.08 (-1.83%)
AMC   4.50 (+0.67%)
PFE   40.38 (+0.50%)
PYPL   73.54 (+1.35%)
NFLX   327.63 (+2.27%)
S&P 500   3,961.65 (+0.33%)
DOW   32,190.48 (+0.27%)
QQQ   310.06 (+0.10%)
AAPL   159.92 (+0.62%)
MSFT   279.01 (+0.49%)
META   205.54 (+0.62%)
GOOGL   105.05 (-0.52%)
AMZN   98.11 (-0.61%)
TSLA   190.19 (-1.06%)
NVDA   266.45 (-2.01%)
NIO   9.03 (-2.59%)
BABA   86.70 (+0.21%)
AMD   97.79 (-2.48%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   60.72 (-1.01%)
CGC   1.92 (+0.52%)
GE   90.86 (-0.80%)
DIS   94.08 (-1.83%)
AMC   4.50 (+0.67%)
PFE   40.38 (+0.50%)
PYPL   73.54 (+1.35%)
NFLX   327.63 (+2.27%)
NASDAQ:CGEN

Compugen - CGEN Stock Forecast, Price & News

$0.75
+0.04 (+5.52%)
(As of 03/24/2023 02:49 PM ET)
Add
Compare
Today's Range
$0.73
$0.77
50-Day Range
$0.68
$1.06
52-Week Range
$0.51
$3.57
Volume
254,387 shs
Average Volume
480,442 shs
Market Capitalization
$65.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Compugen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
744.7% Upside
$6.20 Price Target
Short Interest
Healthy
2.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.41) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

736th out of 989 stocks

Biological Products, Except Diagnostic Industry

130th out of 166 stocks


CGEN stock logo

About Compugen (NASDAQ:CGEN) Stock

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

CGEN Stock News Headlines

The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Why Compugen Shares Are Up Today
Compugen Reports Fourth Quarter and Full Year 2022 Results
Why Shares of Compugen Rose on Thursday
Why Shares of Compugen Rose 16.5% on Wednesday
Why Compugen Stock Crumbled Today
Compugen Reports Third Quarter 2022 Results
SVB Securities Sticks to Its Buy Rating for Compugen (CGEN)
Compugen Announces Receipt of Nasdaq Delisting Notice
See More Headlines
Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

CGEN Company Calendar

Last Earnings
2/27/2023
Today
3/24/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGEN
Employees
73
Year Founded
1993

Price Target and Rating

Average Stock Price Forecast
$6.20
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+513.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-33,690,000.00
Pretax Margin
-448.48%

Debt

Sales & Book Value

Annual Sales
$7.50 million
Book Value
$0.90 per share

Miscellaneous

Free Float
78,396,000
Market Cap
$63.59 million
Optionable
Optionable
Beta
2.70

Social Links


Key Executives

  • Anat Cohen-Dayag
    President, Chief Executive Officer & Director
  • Alberto Sessa
    Chief Financial Officer
  • Zurit Levine
    Vice President-Technology Innovation
  • Eran Ophir
    Vice President-Research & Drug Discovery
  • Henry Adewoye
    Chief Medical Officer & Senior Vice President













CGEN Stock - Frequently Asked Questions

Should I buy or sell Compugen stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGEN shares.
View CGEN analyst ratings
or view top-rated stocks.

What is Compugen's stock price forecast for 2023?

6 brokers have issued 12 month price targets for Compugen's stock. Their CGEN share price forecasts range from $2.00 to $13.00. On average, they anticipate the company's share price to reach $6.20 in the next year. This suggests a possible upside of 771.2% from the stock's current price.
View analysts price targets for CGEN
or view top-rated stocks among Wall Street analysts.

How have CGEN shares performed in 2023?

Compugen's stock was trading at $0.7157 on January 1st, 2023. Since then, CGEN stock has decreased by 0.6% and is now trading at $0.7117.
View the best growth stocks for 2023 here
.

Are investors shorting Compugen?

Compugen saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 2,090,000 shares, an increase of 14.2% from the February 13th total of 1,830,000 shares. Based on an average trading volume of 576,100 shares, the days-to-cover ratio is presently 3.6 days. Approximately 2.6% of the shares of the company are sold short.
View Compugen's Short Interest
.

When is Compugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our CGEN earnings forecast
.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings results on Monday, February, 27th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The biotechnology company earned $7.50 million during the quarter. During the same period in the prior year, the firm posted ($0.10) earnings per share.

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (2.78%), Taylor Frigon Capital Management LLC (1.64%), Renaissance Technologies LLC (1.47%), Macquarie Group Ltd. (0.98%), Two Sigma Investments LP (0.96%) and Morgan Stanley (0.85%).

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $0.71.

How much money does Compugen make?

Compugen (NASDAQ:CGEN) has a market capitalization of $61.65 million and generates $7.50 million in revenue each year. The biotechnology company earns $-33,690,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The official website for the company is www.cgen.com. The biotechnology company can be reached via phone at (723) 765-8585, via email at ir@cgen.com, or via fax at 972-3765-8555.

This page (NASDAQ:CGEN) was last updated on 3/24/2023 by MarketBeat.com Staff